ライフサイエンスコーパス: viral strain

1 with no subsequent detection of the original viral strain).

2 he type of macrophages used and the specific viral strain.

3 with HIV is infected with a new distinct HIV viral strain.

4 ted antiviral CD8(+) T cells, independent of viral strain.

5 y identical individuals infected by the same viral strain.

6 s, to ascertain whether they shared the same viral strain.

7 virus was replaced with the dual-tropic 89.6 viral strain.

8 elopment of disseminated MAC is dependent on viral strain.

9 differed by virus but not by host, gene, or viral strain.

10 have been infected just once with a defined viral strain.

11 expression, promoter usage, methylation, and viral strain.

12 ation and the pathogenicity of the infection viral strain.

13 to the pancreatic tissues was influenced by viral strain.

14 rom these clones as compared to the original viral strain.

15 that the serum was matched to the infecting viral strain.

16 e increased virulence is attributable to the viral strain.

17 say approaches performed separately for each viral strain.

18 t innate immunity, host immune response, and viral strain.

19 ty of ocular disease is partially due to the viral strain.

20 g host antiviral immunity to the transmitted viral strain.

21 ed in pregnant women in response to the H3N2 viral strain.

22 infected individual acquires a distinct new viral strain.

23 tralizing antibodies (bnAbs) against diverse viral strains.

24 osing and superior potency against resistant viral strains.

25 re transport efficiency in other neurotropic viral strains.

26 d to the emergence of biologically different viral strains.

27 l, based on neutralization panels of diverse viral strains.

28 infection even with antigenically homologous viral strains.

29 ng epidemic seasons associated with emergent viral strains.

30 erlie selective transmission of the 4-kappaB viral strains.

31 subjects are coinfected with kappaB-variant viral strains.

32 re not effective in patients harboring these viral strains.

33 t interactions during infections with native viral strains.

34 C01 achieves broad neutralization of diverse viral strains.

35 s that elicit protective immunity to diverse viral strains.

36 in subunits that protect the genomes of many viral strains.

37 s may influence the emergence of reassortant viral strains.

38 20 inhibitory potency varied among different viral strains.

39 may be partially explained by differences in viral strains.

40 the most promising solution to mitigate new viral strains.

41 cross-neutralization between closely related viral strains.

42 s and MN against A/H1N1 and A/H3N2 influenza viral strains.

43 described were evaluated against a range of viral strains.

44 cannot be studied in infections with single viral strains.

45 f both the macrophage- and lymphocyte-tropic viral strains.

46 n ideal environment for the emergence of new viral strains.

47 e exchange of entire genes between different viral strains.

48 roteins which are conserved between multiple viral strains.

49 y result from infection with less-pathogenic viral strains.

50 pite similar rates of replication of the two viral strains.

51 izing activity against HIV-I/MN and HIV-I/3B viral strains.

52 stronger driver of subtype bias to influenza viral strains.

53 orm genetic analyses and distinguish similar viral strains.

54 ble of neutralizing up to 59% of 208 diverse viral strains.

55 logy of the vector populations, and evolving viral strains.

56 ART access or adherence, and drug-resistant viral strains.

57 ir and tBLASTx identified a higher number of viral strains.

58 utralizing Ab response against multiple H1N1 viral strains.

59 ralization-resistant variants in circulating viral strains.

60 single antibody is highly active against all viral strains.

61 neutralizing antibody breadth to a panel of viral strains.

62 reas HuH6 cells were only permissive to some viral strains.

63 Abs when evaluated on a panel of 21 diverse viral strains.

64 to repress the replication of several HIV-1 viral strains 10- to 100-fold in T-cell lines and primar

65 ng this strategy, we have isolated three axl viral strains (1B1, SV8, and FFa4) that show augmented 3

66 we demonstrate that, in contrast to an acute viral strain, a persistent viral isolate leads to long-t

67 These cells were much less susceptible to viral strains AD169varATCC, TownevarRIT(3), and Toledo.

68 mics, occasional global pandemics occur when viral strains adapt to humans from other species.

69 rus vaccines are composed of live-attenuated viral strains administered to infants orally at 6-8 week

70 egions of the HCMV genome in three different viral strains all required prior expression of the viral

71 eal-time quantitative PCR; the most virulent viral strain also replicated to the highest level in fis

72 Infection with pathogenic viral strains alters cell-cell and cell-matrix interacti

73 ine infecting genotypes, RAVs, comprehensive viral strain analysis, and quasispecies diversity.

74 e during cytomegalovirus infection depend on viral strain and dose, as well as the quality of the T c

75 This inhibition is independent of viral strain and is dose dependent.

76 the Delta variant to become the predominant viral strain and led to a surge in cases in a university

77 The viral strain and the combination of mutant viral genes t

78 We have characterized the viral strain and the sequence of commonly recognized cyt

79 5 contains elements that support usage by X4 viral strains and demonstrate that the gp120 interaction

80 low nanomolar anti-HIV-1 activity toward two viral strains and encouraging selectivity indexes.

81 es with limited potency against heterologous viral strains and genotypes.

82 on the correct prediction of the circulating viral strains and is limited by the time constraint of t

83 ved nature of this protease across different viral strains and its crucial role in viral maturation a

84 must provide information for a wide range of viral strains and lineages.

85 but reinfections with antigenically distinct viral strains and subtypes are common.

86 such as antigenic variability of circulating viral strains and the ability of viruses to undergo neut

87 a critical step in the identification of new viral strains and the subsequent use of such strains or

88 The establishment of distinct viral strains and their variable circulation patterns pr

89 The emergence of drug-resistant viral strains and uncertain vaccine prospects highlight

90 In contrast, viral strains and variants that bind with low affinity t

91 neutralization panels comprising 181 diverse viral strains and with available antibody-antigen comple

92 nduced toxicity, emergence of drug-resistant viral strains, and financial constraints.

93 coinfection of individuals by two different viral strains, and for cross-species transmission of FIV

94 ustly predict the relative fitness of mutant viral strains, and indicate the potential value of this

95 nce of certain phenotypic characteristics of viral strains, and inform strain selection and trial des

96 es showed high conservation across different viral strains, and therefore could be attractive targets

97 o control virus spread differed between HCMV viral strains, and this phenomenon was dependent on amin

98 rum neutralization data for a set of diverse viral strains, and uses a mathematical model to identify

99 Viral strains are indistinguishable serologically, altho

100 Antibodies that can neutralize diverse viral strains are likely to be an important component of

101 Receptor binding avidities of viral strains are not usually taken into account when in

102 s (NAbs) against the majority of circulating viral strains as a result of antibody evasion mechanisms

103 each of these targets in the above-mentioned viral strains, as well as several primary isolates, woul

104 lly occurring VRC01-sensitive and -resistant viral strains, as well as their mutated sensitive or res

105 f ongoing infection, the presence of a novel viral strain associated with MM, or underlying immunodef

106 Many viral strains associated with BKV-ISN are difficult to c

107 influenza strain, produce Abs against older viral strains at the expense of responses to novel, prot

108 d generation inhibitors with potency against viral strains bearing drug resistant IN substitutions is

109 f murine leukemia virus (MLV), but only with viral strains bearing N-tropic CA.

110 s also the probability of new drug-resistant viral strains being created, is proportional to the tota

111 Viral strains belonging to both HHV-6 subgroups (A and B

112 r there were differences in the pretreatment viral strains between African American patients and whit

113 n geometric mean titers for any of the three viral strains between groups (P=0.69 for H1N1, P=0.56 fo

114 , coinfection of CD34(+) cells with clinical viral strains blocked the ability of an HDAC inhibitor t

115 les that of its counterpart from the related viral strain bovine papillomavirus type 1, the precise p

116 the mechanisms by which E2 from the related viral strains bovine papillomavirus-1 and human papillom

117 , provided some protection to the homologous viral strain but no protection against infection by infl

118 n of CD34(+) cells with a laboratory-adapted viral strain but not with clinical strains.

119 cination approaches protect against specific viral strains, but do not consistently induce broad and

120 tations from specific antibodies in specific viral strains, but it remains unclear how much the effec

121 New viral strains can be evolved to recognize different host

122 trate that individuals infected with similar viral strains can generate partially similar antibody re

123 y which severely compromised, drug-resistant viral strains can increase fitness levels.

124 Viral strain characteristics likely contribute to oral H

125 However, the overall congruence of viral strain classification based on either VP1 or LTA p

126 The last pair showed evidence of viral strain concordance between mother and child but al

127 The new viral strains contain an additional NF-kappaB, NF-kappaB

128 learance and evolution in HCV infection, and viral strains containing epitope variants that are less

129 ique because there are repeated exposures to viral strains containing genetically conserved epitopes

130 ers suggest that maternal reinfection by new viral strains could be a major source of congenital infe

131 This, coupled with evidence that viral strains could naturally differ in virulence, sugge

132 ith reactivity against an array of influenza viral strains could reduce the need for yearly influenza

133 In mice, accelerated clearance of a new viral strain (cross-protection) can be elicited by prior

134 Viral strains, defined by differences in SFV gag sequenc

135 ression by tetraspanins varied for different viral strains, despite comparable recruitment of their E

136 The UL36 proteins from the three viral strains differ by several amino acid substitutions

137 dromic DNA sequence, proteins from different viral strains differ in their abilities to discriminate

138 smatch, when the vaccine and the circulating viral strains differ.

139 Here, we report a viral strain difference in the morphology of these inclu

140 ied the mORV mu2 protein as a determinant of viral strain differences in the transcriptase and nucleo

141 replication rate (fitness) of a bacterial or viral strain directly depends on the copy number of fold

142 gion of a chromosome is duplicated, multiple viral strains diverging at a "super-spreading" event, an

143 model of EBV+ DLBCL was developed, using the viral strain EBV WIL, which unlike common laboratory str

144 ptor utilizing HIV-1(ADA) and subtype C 1157 viral strains elicited productive viral replication and

145 However, new viral strains emerge continuously because of the plastic

146 ctions originating from a single transmitted viral strain, estimation of the most recent common ances

147 ections can boost antibody responses against viral strains first encountered in childhood through a p

148 n this high-risk group, the emergence of new viral strains following treatment failure is most common

149 ssion is thought to determine the tropism of viral strains for different cell types, and also to infl

150 l facilitate the construction of recombinant viral strains for identifying viral determinants of CMV

151 Because so few of the viral strains formed factories that were regularly assoc

152 We isolated two H7N9 viral strains from environmental samples associated with

153 gions of the viral genome, relatedness among viral strains from geographically diverse regions, and e

154 yavirus groups based on live isolation of 26 viral strains from mosquitoes (Jonchet virus [JONV], eig

155 o were first infected in childhood with H3N2 viral strains from the 1960s and 1970s possess non-neutr

156 ious studies have attempted to predict which viral strains future epidemics may arise from using infe

157 provides experimental evidence that the new viral strains gained a potential selective advantage as

158 Inaccuracies in prediction of circulating viral strain genotypes and the possibility of novel reas

159 vaccines, immunizations with live attenuated viral strains have proven most effective, but the vaccin

160 an alignment of antigen sequences of diverse viral strains; (ii) neutralization data for the antibody

161 Coreceptor tropism testing of viral strains in an individual patient is necessary prio

162 ective against wild-type and NNRTI-resistant viral strains in cell culture.

163 enetic analyses across replication-competent viral strains in databases.

164 paB viruses dominate the 3-kappaB "isogenic" viral strains in pairwise competition assays in T-cell l

165 ing properties to various degrees on several viral strains in rats and mice.

166 ead of replication-competent, drug-resistant viral strains in the population and to infer the consequ

167 ed by a polymorphism present in pre-existing viral strains in the underlying population, and not a mu

168 HIV-1MN) and macrophage-tropic (HIV-1JR-CSF) viral strains in vitro.

169 es and host cellular response, and genotyped viral strains, in monozygotic (MZ) and dizygotic (DZ) tw

170 ition antibody titres in serum for the three viral strains included in the vaccine.

171 been reproduced with several cell types and viral strains, including low-passage isolates.

172 potency and breadth in neutralizing multiple viral strains, including neutralization escape viruses d

173 viduals were not inhibitory to some R5-HIV-1 viral strains indicating that certain HIV-IgM may lack A

174 r, these changes suggest that the attenuated viral strain induces an "activation" of macrophages, whi

175 will occur is likely to hinge on whether the viral strains involved in the current outbreak acquire a

176 The dominance of the 4-kappaB viral strains is also evident in the natural context whe

177 bNAbs) capable of neutralizing various HIV-1 viral strains is challenging, but understanding how a su

178 rate, the appearance of novel drug-resistant viral strains is common.

179 tudies showed that infection by CXCR4-tropic viral strains is mediated by the galactosylceramide rece

180 mining the effectiveness of NAIs against new viral strains is vital for deciding how to use the stock

181 hat UL88, which is conserved among different viral strains, is dispensable for production of infectio

182 Viral strains isolated from healthy subjects and from pa

183 The 2 vaccines are derived from different viral strains: JE-VC from the SA14-14-2 strain and JE-MB

184 The Env gp120 proteins from four viral strains (JRFL, YU2, 89.6, and HXB2) and their corr

185 HeLa cells by wild-type HSV-1 and by RP5, a viral strain lacking the VP16 transcriptional activation

186 in; however, the egg-adapted version of this viral strain lacks the new putative glycosylation site.

187 near-complete removal of junk Env from many viral strains, leaving trimers and viral infectivity lar

188 cities and the development of drug-resistant viral strains may limit the effectiveness of this strate

189 ese patients, suggesting that drug-resistant viral strains might achieve replication levels comparabl

190 29 SV(ev) mice infected with a neurovirulent viral strain, neuroadapted Sindbis virus (NSV).

191 oenteritis after challenge with a homologous viral strain, Norwalk virus (genotype GI.1).

192 inducing a cross-reactive immune response to viral strains not found in the vaccine.

193 tide sequencing and phylogenetic analysis of viral strains obtained demonstrated that STLV-1 strains

194 the long-term impacts of outbreak-associated viral strains on patients and medical systems, mNGS cons

195 The effect of viral strains on the outcome of congenital CMV is debate

196 LMP1 from the Cao viral strain or LMP1 homologues from the simian EBV natu

197 to confounding factors, such as age-specific viral strains or cohabitation of patients.

198 ination, and changes in dominant circulating viral strains over time, a time-matched cohort study was

199 enic memory T cell populations, using mutant-viral strains, peptide-based tolerization strategies, or

200 tcome of an SV40 infection may depend on the viral strain present.

201 tudy aimed to analyze env genes of subtype-E viral strains, prevalent in Asia and Africa, with a nonh

202 ions on env have been conducted on subtype-B viral strains, prevalent in North America and Europe.

203 had NAbs that could neutralize their second viral strains prior to their reinfection, suggesting tha

204 pecific groups of mutations across different viral strains, providing valuable insights into the viru

205 e approaches are losing effectiveness as new viral strains quickly develop drug resistance.

206 ver, or spleen, providing a nidus for future viral strain recombination.

207 TAR-VIR can be used standalone for viral strain reconstruction from metagenomic data.

208 d that repeated immunization with the second viral strain relieved the effects of original antigenic

209 proteases involved in the activation of many viral strains remain unidentified.

210 RFLP patterns distinguish between different viral strains remains unclear.

211 a phase 1 study of a CHIKV vaccine against 9 viral strains representing all 3 genotypes.

212 alization potency data over a set of diverse viral strains representing the antigen, and enhanced acc

213 etroviral field in light of the emergence of viral strains resistant to contemporary clinically used

214 nza vaccine, added to the rapid emergence of viral strains resistant to current therapy make the need

215 neutralized the heterologous tier 2 clade B viral strain RHPA, which was used to design resurfaced g

216 CpG [corrected] methylation often change and viral strain selection may occur.

217 there must be ongoing viral replication, and viral strains should thus evolve.

218 d the cocirculation in the index case of two viral strains showing a different insertion at the hemag

219 in African-born AGMs infected with the same viral strain (SIVagm.sab92018).

220 altered the tropism of the dualtropic 89.6P viral strain so that it infected only CXCR4(+) cells.

221 , no single bNAb effectively neutralizes all viral strains, so induction of multiple neutralizing mon

222 hus, the HSV-1 genome copy number profile is viral strain specific and positively correlates with the

223 infection-inducing co-receptor, it mediates viral strain-specific gp120-induced calcium signaling at

224 ystem responds to infections in a remarkably viral strain-specific manner.

225 atures in the intestine, as well as numerous viral-strain-specific responses that persisted.

226 Abs are not protective or are too narrow in viral strain specificity.

227 o almost exclusive Ab responses to the first viral strain, suggesting that original antigenic sin cou

228 different individuals infected with the same viral strain, suggesting that the degree of positive pre

229 Ongoing viral strain surveillance facilitated the rapid implemen

230 e-tropic HIV-1 isolates, T-cell line-adapted viral strains tend to be insensitive to their suppressiv

231 factor receptor superfamily, and all primary viral strains tested to date use CD134 for infection.

232 were equivalent in monkeys infected with the viral strains tested, documenting strong adaptive immune

233 d productive infection by one or more of the viral strains tested.

234 ent SV vector (dsNSV) was constructed from a viral strain that causes both prominent spinal cord infe

235 emotional behaviors, it is unknown whether a viral strain that is not neurotropic (A/PR/8/34) can res

236 RNA at the time of death (P = 0.004) and the viral strain that predominated in the brain frequently w

237 ghly pathogenic dual-tropic chimeric SIV-HIV viral strain that results in rapid loss of both SHIV-sus

238 NV1066 is a novel oncolytic herpes viral strain that specifically infects cancer cells and

239 The appearance of viral strains that are resistant to protease inhibitors

240 dons might help identify the most fit extant viral strains that arise during antigenic drift.

241 izes the importance of subtle differences in viral strains that determine disease outcomes.

242 ided insights into their precursors, and the viral strains that engage them, as well as defined how s

243 rapy of HIV-1 infection is the appearance of viral strains that exhibit resistance to protease inhibi

244 transmission cycles, genetic changes in EEE viral strains that resulted in increased human virulence

245 alization have enabled the identification of viral strains that show enhanced reactivity for V2 precu

246 s infected with the current circulating H3N2 viral strain (that possesses the glycosylation site) and

247 N1 influenza HA protein were affected by the viral strain the individual was originally exposed.

248 esistant variants can be generated with both viral strains, the underlying mechanism is clearly diffe

249 potentially resulting in emergence of novel viral strains through recombination.

250 velope determine which receptor is used by a viral strain to enter host cells.

251 hese ends, we studied the ability of diverse viral strains to affect intracellular signaling and apop

252 Selection of viral strains under ALLINI pressure has revealed an A128

253 Influenza viral strains undergo rapid mutations of the surface pro

254 ggesting that reduced uptake of heterologous viral strains underlays this lack of sensing.

255 s limited by the emergence of drug-resistant viral strains upon prolonged therapy.

256 ients with established HIV-1 infection, some viral strains use an alternative coreceptor for HIV-1 en

257 ring primary infection were dependent on the viral strain used for the infection but not on the host.

258 these antibodies are mostly specific to the viral strains used in the vaccine.

259 We analyzed the VP1 sequences of the viral strains using the UPGMA method with uncorrected pa

260 nfounding variables in these studies include viral strains utilized (17syn(+) versus KOS), anatomical

261 n young-animal models and against homologous viral strains, vaccine efficacy has not been thoroughly

262 not differ between sigma1s(-) and sigma1s(+) viral strains, virus-induced caspase-3 activation and re

263 virus (HCV) superinfection with a divergent viral strain was determined in a cohort of recently infe

264 tera exigua nucleopolyhedrovirus (SeMNPV), a viral strain was plaque-purified and named vAcRev.

265 Seroconversion to at least one viral strain was seen in 15 (68%) of 22 patients in the

266 The highest VE against all viral strains was observed in adults aged 18-54 years (5

267 The highest VE against all viral strains was observed in adults aged 18-54 years (5

268 Emergence of resistant viral strains was variable, with some individuals remain

269 ing genome segments derived from two natural viral strains, we examined both the fitness costs of ext

270 s, each challenged with one of four distinct viral strains, we found resistance led to a 46% decrease

271 reflects the antigenic composition of local viral strains, we hypothesize that convalescent plasma h

272 Intriguingly, none of the viral strains were able to transform the murine cell lin

273 Coinfections with genetically distinct viral strains were detected in some cases, and rearrange

274 When LAIV followed IIV, 21 of 45 viral strains were identified.

275 With LAIV-LAIV, the fewest viral strains were recovered (3/33)--numbers significant

276 Twenty-eight of 39 possible influenza viral strains were recovered after the initial dose of L

277 association by the mu2 core proteins of some viral strains, which form filamentous factories, than by

278 ol is a result of infection with a defective viral strain, while others suggested host immune factors

279 ife history stages, natural selection favors viral strains whose virion production rate maximizes vir

280 ively infected stage, the more likely that a viral strain will persist.

281 isingly, neuropathology differs depending on viral strain with a French Polynesian isolate producing

282 le bispecific antibody can neutralize 97% of viral strains with a high overall potency.

283 preventive efficacy with current patterns of viral strains with combination monoclonal antibody thera

284 als in need of vaccination would profit from viral strains with defined attenuation mechanisms.

285 ode of evolution is a red queen race between viral strains with different beneficial mutations.

286 increased antiviral activity when exposed to viral strains with differential abilities to downmodulat

287 ediction based on antibody neutralization of viral strains with diverse sequences and validated the a

288 ate the utility of DNA shuffling in breeding viral strains with improved characteristics for gene the

289 SARS-CoV-2 pandemic, the emergence of novel viral strains with increased transmission rates poses a

290 , even though monocytes also express CD4 and viral strains with macrophage (M)-tropic phenotypes pred

291 n indicating constraints on the viability of viral strains with multiple mutations.

292 Moreover, cells infected with viral strains with mutations in the release inhibitor A3

293 mine the Gn pig's A/H phenotype and to match viral strains with previously determined HuNoV VLP bindi

294 us (HIV) infection have been found to harbor viral strains with reduced susceptibility to antiretrovi

295 module, our sensors can discriminate between viral strains with single-base resolution.

296 distinct temporal response kinetics between viral strains, with HPAI inducing the most rapid respons

297 Superinfection of different viral strains within a single host provides an opportuni

298 quencing to account for the diverse array of viral strains within an infected individual.

299 viral replication by >2,000-fold in multiple viral strains without impacting cell viability.

300 rid pipeline named TAR-VIR that reconstructs viral strains without relying on complete or high-qualit